All IndicationsInfectious DiseasePhase 3Phase 3Phase 3Phase 2Phase 2Phase 2Phase 2
🦠
Hepatitis C
5
Companies
7
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
VRTX
Vertex Pharmaceuticals Incorporated
Telaprevir
4503.T
Astellas Pharma Inc.
Interferon alfacon-1
MRK
MERCK
Elbasvir
AVIR
Atea Pharmaceuticals, Inc.
AT-527
VRTX
Vertex Pharmaceuticals Incorporated
VX-950
CLRB
Cellectar Biosciences, Inc.
NOV-205
VRTX
Vertex Pharmaceuticals Incorporated
telaprevir or matching placebo
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | Telaprevir | Phase 3 | — | — | — |
| 4503.T Astellas Pharma Inc. | Interferon alfacon-1 | Phase 3 | — | — | — |
| MRK MERCK | Elbasvir | Phase 3 | — | — | — |
| AVIR Atea Pharmaceuticals, Inc. | AT-527 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | VX-950 | Phase 2 | — | — | — |
| CLRB Cellectar Biosciences, Inc. | NOV-205 | Phase 2 | — | — | — |
| VRTX Vertex Pharmaceuticals Incorporated | telaprevir or matching placebo | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
3
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.